Coronavirus: The United States grants an emergency license for the Pfizer Bionic vaccine and launches a massive vaccination process
The scientific director of the influential American Drug Agency (FDA) announced in a statement that the Pfizer Bionic vaccine, which received an emergency license to combat the Coronavirus, was permitted to be used. After that, US President Donald Trump announced the launch of a massive operation to distribute the vaccine throughout the United States, as he tweeted Friday on Twitter, saying, "The first vaccinations will take place in less than 24 hours." The CEO of Germany's Biontech said that the challenge today is to scale up manufacturing to meet broad demand.
On Friday, the United States granted an emergency permit for the Pfizer / Biontech vaccine to treat Covid-19 infections, the Scientific Director of the FDA said in a statement.
A huge logistical operation will be launched immediately in the coming hours, to distribute the vaccine throughout the country.
On Friday, the outgoing US President Donald Trump announced that the first vaccinations against Covid-19 will begin "in less than 24 hours" in the United States, after the US Medicines Agency approved the Pfizer-Bionic vaccine.
"We have already started sending the vaccine to all states," Trump said on Twitter, adding, "The first vaccinations will take place in less than 24 hours."
The Republican president added, "Governors decide where vaccines should go in their states and who will receive them first." "We want our older citizens, caregivers and first aid to be the first to receive it," he added.
The US Food and Drug Administration has not previously green-lighted a new vaccine so quickly.
The Washington Post reported Friday that the White House ordered the President of the US Food and Drug Administration (FDA) to authorize the Pfizer-Bionic vaccine on the same day, that is, Friday, or to submit his resignation.
The commission's decision was expected by the end of the week anyway, but Trump tweeted Friday morning that the organization was "a big slow turtle."
The CEO of the German company Biontech said that the biggest challenge facing it and its partner Pfizer now that the Covid-19 vaccine has been authorized in the United States will be to increase manufacturing to meet the huge demand.
Ugur Shaheen said in an interview, "We have to solve the problem of manufacturing. It is very clear that more doses are needed. We are addressing this issue, which is how to produce more doses." The two companies said they will produce up to 1.3 billion doses of the vaccine next year.